1. |
杨春明. 乳腺癌治疗的现代概念[J]. 中国普外基础与临床杂志, 2008; 15(17): 467470.
|
2. |
Basco VE, Coldman AJ, Elwood JM, et al. Radiation dose and second breast cancer [J]. Br J Cancer, 1985; 52(3): 319325.
|
3. |
Fowble B, Hanlon A, Freedman G, et al. Second cancers after conservative surgery and radiation for stages ⅠⅡ breast cancer: identifying a subset of women at increased risk [J]. Int J Radiat Oncol Biol Phys, 2001; 51(3): 679690.
|
4. |
Brot P, de la Rochefordière A, Scholl SM, et al. Contralateral breast cancer: annual incidence and risk parameters [J]. J Clin Oncol, 1995; 13(7): 15781583.
|
5. |
Unnithan J, Macklis RM. Contralateral breast cancer risk [J]. Radiother Oncol, 2001; 60(3): 239246.
|
6. |
Silverman JS, Anderson P, Freedman G. Contralateral breast cancers within 5 years of conservative surgery and radiation: Implications for breast MRI [J]. Int J Radiat Oncol Biol Phys, 2007; 69(3): S211.
|
7. |
Hermanek P, Sobin LH eds. TNM classification of malignant tumours [M]. 4th ed. Berlin New York: SpingerVerlag, 1987: 5658.
|
8. |
田野. 乳腺癌放射治疗简介[J]. 实用临床医药杂志, 2008; 12(2): 3032.
|
9. |
袁家宾, 林洋, 刘洪, 等. 早期乳腺癌保乳手术的疗效分析[J]. 中国普外基础与临床杂志, 2008; 15(7): 477478.
|
10. |
Gralow J, Ozols RF, Bajorin DF, et al. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology [J]. J Clin Oncol, 2008; 26(2): 313325.
|
11. |
Chen Y, Thompson W, Semenciw R, et al. Epidemiology of contralateral breast cancer [J]. Cancer Epidemiol Biomarkers Prev, 1999; 8(10): 855861.
|
12. |
Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for earlystage breast cancer: a populationbased study[J]. Int J Radiat Oncol Biol Phys, 2003; 56(4): 10381041.
|
13. |
Cook LS, White E, Schwartz SM, et al. A populationbased study of contralateral breast cancer following a first primary breast cancer (Washington United States) [J]. Cancer Causes Control, 1996; 7(3): 382390.
|
14. |
MericBernstam F. High risk of contralateral breast carcinoma in women with hereditary/familial nonBRCA1/BRCA2 breast carcinoma [J]. Breast Diseases, 2007; 17(4): 340345.
|
15. |
Storm HH, Andersson M, Boice JD Jr, et al. Adjuvant radiotherapy and risk of contralateral breast cancer[J]. J Natl Cancer Inst, 1992; 84(16): 12451250.
|
16. |
Mertens WC, Hilbert V, MakariJudson G. Contralateral breast cancer: factors associated with stage and size at presentation[J]. Breast J, 2004; 10(4): 304312.
|
17. |
Harvey EB, Brinton LA. Second cancer following cancer of the breast in Connecticut, 193582 [J]. Natl Cancer Inst Monogr, 1985; 68: 99103.
|
18. |
Obedian E, Fischer B, Haffty BG. Second malignancies after treatment of earlystage breast cancer: lumpectomy and radiation therapy versus mastectomy [J]. J Clin Oncol, 2000; 18 (12): 24062412.
|
19. |
Thierry Petit, 任国胜, Patrick Dufour, 等. 乳腺癌辅助内分泌治疗 [J]. 中国普外基础与临床杂志, 2007; 14(3): 248250.
|
20. |
Brenner H, Siegle S, Stegmaier C, et al. Second primary neoplasms following breast cancer in Saarland, Germany, 19681987[J]. Eur J Cancer, 1993; 29A(10): 14101414.
|
21. |
Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: an overview of randomized trials[J]. Lancet, 1998; 351(9114): 14511467.
|
22. |
杨金巧. 乳腺癌的内分泌治疗及研究进展 [J]. 中国普外基础与临床杂志, 2004; 11(1): 1214.
|
23. |
Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph nodenegative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B14 randomized trial [J]. J Natl Cancer Inst, 2001; 93(9): 684690.
|
24. |
Kurtz JM, Amalric R, Brandone H, et al. Contralateral breast cancer and other second malignancies in patients treated by breastconserving therapy with radiation[J]. Int J Radiat Oncol Biol Phys, 1988; 15(2): 277284.
|
25. |
Yadav BS, Sharma SC, Patel FD, et al. Second primary in the contralateral breast after treatment of breast cancer [J]. Radiother Oncol, 2008; 86(2): 171180.
|
26. |
Fowble B, Hanlon A, Freedman G, et al. Internal mammary node irradiation neither decreases distant metastases nor improves survival in stage Ⅰ and Ⅱ breast cancer[J]. Int J Radiat Oncol Biol Phys, 2000; 47(4): 883894.
|